Weight Regain After Stopping Jabs: Can Pills Help Maintain Results?

Weight loss injections like Wegovy and Mounjaro have changed the conversation around treating obesity. They reduce appetite, quieten cravings and make calorie control seem more achievable for many. But as more and more people hit their target weight or contemplate stopping treatment, a question is growing in importance, what happens after the injections stop?

The honest answer is that weight regain can happen. This does not mean someone has "failed." Instead, it reflects how strongly the body defends weight, appetite, and energy balance after weight loss. Research on semaglutide found that one year after stopping treatment, participants regained around two-thirds of the weight they had previously lost, and many health improvements moved back towards baseline.

Why Weight Often Comes Back After Stopping Jabs

GLP-1 and dual GLP-1/GIP medicines work partly by reducing appetite, increasing fullness, and slowing stomach emptying. When treatment stops, the biological support that made eating less feel easier may reduce. Hunger can return, portion sizes may increase, and old eating patterns can slowly come back.

This is why obesity is increasingly treated as a long-term, relapsing condition rather than a short-term cosmetic issue. A 2026 Oxford review reported that people tend to regain weight after stopping weight-loss medicines, with newer medicines such as semaglutide and tirzepatide linked to faster regain than older behavioural programmes in the available data.

Can Pills Help Maintain Results?

Possibly, but it depends on the pill. Currently, the best-known oral option already used for weight management in the UK is orlistat. Orlistat does not work like Wegovy or Mounjaro. It reduces the amount of fat absorbed from food, while GLP-1 injections mainly affect appetite and fullness signals. The NHS states that orlistat may help prevent weight gain and may help with weight loss, but it must be used alongside diet and exercise.

However, the more exciting development is the rise of oral GLP-1 medicines, especially orforglipron. This type of pill is designed to work more like GLP-1 injections, but without the injection. Early evidence suggests it may help some people maintain weight loss after stopping injectable treatment, although UK availability and guidance still matter.

The New Pill Everyone Is Watching: Orforglipron

A phase 3b trial called ATTAIN-MAINTAIN studied people who had already lost weight after 72 weeks on either tirzepatide or semaglutide. Participants then switched to either once-daily orforglipron or placebo for weight maintenance. The Nature Medicine paper concluded that once-daily orforglipron helped minimise weight changes after weight reduction achieved with tirzepatide or semaglutide.

In Lilly’s trial announcement, people switching from Wegovy to orforglipron maintained nearly all of their previously achieved weight loss on average, with a reported average difference of 0.9 kg after 52 weeks. Those switching from Zepbound/tirzepatide maintained most of their previous loss as well, although with a larger average difference of 5.0 kg.

Does This Mean Pills Can Replace Jabs?

Not exactly. Pills may become a useful maintenance option, but they should not be seen as a simple swap for everyone. Some people may need ongoing injectable treatment. Others may benefit from a lower-dose maintenance plan. Some may use tablets, while others may manage with lifestyle support and clinical monitoring.

The key point is that maintenance needs a plan. In the SURMOUNT-4 trial, people who continued tirzepatide maintained more weight loss, while those who switched to placebo regained a substantial amount. The researchers noted that the results support the need for continued pharmacotherapy in many patients to maintain weight reduction and related health improvements.

What About the UK?

In the UK, current NHS information lists orlistat, liraglutide, semaglutide, and tirzepatide among medicines used for weight management, with treatment decisions based on clinical suitability and professional prescribing. The NHS also states that weight management medicines should be used alongside a reduced-calorie diet and increased physical activity.

Orforglipron is not yet a routine UK weight management option under NICE guidance. NICE currently lists orforglipron for managing overweight and obesity as guidance in development, with an expected publication date of 18 November 2026.

Why Lifestyle Still Matters After Medication

Medication can make weight loss easier, but long-term maintenance still needs behaviour change. That includes protein-focused meals, fibre, regular movement, sleep support, alcohol awareness, stress management, and realistic portion control. Without these habits, stopping treatment can feel like removing the “brake” from appetite.

The NHS notes that maintaining weight may require continued attention to food intake and physical activity, and people may need more activity to avoid regaining weight after living with obesity.

Who Might Benefit from a Pill-Based Maintenance Plan?

A pill-based plan may suit people who have reached a stable weight but do not want to remain on injections long term. It may also help people who struggle with needles, travel frequently, or want a more convenient treatment route. However, this decision should always depend on medical history, side effects, BMI, weight-related conditions, current medicines, and pregnancy plans.

It is also important to remember that “maintenance” does not always mean staying at exactly the same weight. For some people, successful maintenance may mean keeping most of the weight off, preventing rapid regain, or protecting improvements in blood pressure, cholesterol, blood sugar, and mobility.

The Bottom Line

Yes, pills may help maintain weight loss after stopping jabs, but the answer is not as simple as “stop injections and start tablets.” Orlistat is already available in the UK, but it works differently and is not a direct replacement for GLP-1 injections. Newer oral GLP-1 medicines such as orforglipron look promising, especially after the latest maintenance trial data, but UK guidance and access are still developing.

For now, the safest approach is to treat weight maintenance as part of the treatment journey, not an afterthought. Before stopping Wegovy, Mounjaro, or any weight loss injection, patients should speak with a qualified prescriber about tapering, switching, ongoing treatment, lifestyle support, and realistic monitoring.